Trial · NCT04771000
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
NCT04771000, Phase 2, Terminated, Noorik Biopharmaceuticals AG
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19. Trials, record NCT04771000. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04771000
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
- NCT number
- NCT04771000
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 88 participants, actual
- Lead sponsor
- Noorik Biopharmaceuticals AG
- Conditions
- Covid19, Hypoxemia
- Interventions
- Ambrisentan, Placebo
- First posted
- 2021-02-25
- Last updated
- 2023-03-21
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects alive and not having developed respiratory failure from randomization to Day 14 | 30 days | The number of patients that are alive and have not developed respiratory failure by day 30 after entering the study will be compared between the experimental and placebo arms |
| Secondary | Proportion of subjects alive and free of respiratory failure at Day 14 and Day 30 | 14 days and 30 days | The number of patients that are alive and have not developed respiratory failure on day 14 will will be compared between the experimental and placebo arms |
| Secondary | Proportion of subjects alive and not requiring oxygen supplementation or higher respiratory support at Day 14. | 14 days | The number of patients not requiring supplemental oxygen, or any other type of respiratory support at day 14 will be compared between the experimental and placebo arms |
| Secondary | Time to hospital discharge (up to Day 30) | 30 days | The time in days required for subjects to be discharged from the first hospitalisation will be estimated and compared between the experimental and placebo groups |
| Secondary | Proportion of subjects admitted to the Intensive Care Unit or High-Dependency Unit (up to Day 30) | 30 days | The number of patients who qualified for admission or where admitted to an intensive care or a high-dependency unit at any time during the first 30 days after entering the study will be estimated and compared between the experimental and placebo groups |
| Secondary | Time until weaning from oxygen therapy (up to Day 30) | 30 days | The time in days subjects required to breathe independently and without oxygen support will be estimated and compared for the experimental and placebo groups |
| Secondary | Time until weaning from respiratory support other than low-flow oxygen supplementation for subjects having developed respiratory failure (up to Day 30) | 30 days | The time in days subjects required to breathe independently with or without supplemental oxygen will be estimated and compared for the experimental and placebo groups |
| Secondary | Change in SpO2/FiO2 from baseline to the time-weighted average obtained on Day 3 | 3 days | The difference in blood oxygen saturation (SpO2) corrected by the inspired fraction of oxygen (FiO2) between baseline and the time-adjusted average calculated for day 3 will be compared between the experimental and placebo arms |
| Secondary | Change in SpO2/FiO2 from baseline to the time-weighted average obtained on Day 1 | 1 day | The difference in blood oxygen saturation corrected by the inspired fraction of oxygen between baseline and the time-adjusted average calculated for day 1 will be compared between the experimental and placebo arms |
| Secondary | Change in SpO2/FiO2 from baseline to the time-weighted average obtained on Day 2 | 2 days | The difference in blood oxygen saturation corrected by the inspired fraction of oxygen between baseline and the time-adjusted average calculated for day 2 will be compared between the experimental and placebo arms |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04771000
GET https://conductscience.org/api/trials/v1/NCT04771000/registered